Court source summary

2026-01-26

MDL 3163 Court Page

This page explains what MDL 3163 is, why the GLP-1 and NAION litigation matters, and which court-managed materials visitors should understand first inside the site.

  • Eastern District of Pennsylvania
  • Official source summary
  • Re-checked March 30, 2026

What is MDL 3163?

MDL 3163 is a federal multidistrict litigation created in December 2025 to centralize lawsuits alleging that GLP-1 receptor agonists may be linked to NAION, a serious optic-nerve condition associated with sudden vision loss.

The litigation groups federal cases involving medications such as Ozempic, Wegovy, Saxenda, Trulicity, and related GLP-1 receptor agonists that are widely prescribed for type 2 diabetes and weight management.

This summary page explains the court background first, so visitors can understand the key court context without leaving the site.

  • Created by the JPML in December 2025 and assigned to the Eastern District of Pennsylvania
  • Focuses on GLP-1 receptor agonist cases involving alleged NAION vision loss
  • Used as the central federal court track for public MDL 3163 materials

Why this litigation matters

This litigation matters because public research and regulatory review have kept GLP-1, semaglutide, NAION, and vision loss under active discussion. At the same time, the court process is testing how manufacturers described potential risks and how those allegations should be handled in one coordinated forum.

For visitors, the practical question is not whether every case will be the same, but whether their own medication history, symptom timing, and medical records make further review worth considering.

  • Some public research has discussed a possible association between semaglutide and NAION, while later findings are still being evaluated
  • EMA has recommended updating semaglutide labeling so NAION is listed as a very rare adverse reaction
  • A federal MDL means lawsuit developments, scheduling orders, and court materials are now being handled in a single public track

What you can review from this court page

The MDL 3163 court page works best as the official starting point for court-managed materials. It helps attorneys, plaintiffs, and the public follow the litigation from one court landing page instead of searching across multiple sources.

It is also useful for understanding what the court itself is making available publicly, and what may still require a separate docket system such as PACER.

  • Case management orders and scheduling updates
  • Conference access details and hearing-related notices
  • Judge and chambers contact information kept on the MDL page
  • Links outward to the broader court record, while deeper filings and motions may still require docket access